The findings of MEK inhibitors trametinib and cobimetinib, and BRAFV600-mutatant-related dabrafenib considered as therapeutic strategies of cancers demonstrated the importance of 309 dysregulated genes in colorectal cancer. This evidence concerns the gene MAP2K7 and colorectal cancer.